MOTS-c and Gabapentin Interaction: Safety, Pharmacology, and Clinical Guidance

Why No Formal Interaction Data Exists

MOTS-c remains an investigational peptide without FDA approval, which means it has not been run through the standard battery of in vitro and in vivo drug interaction studies required under FDA guidance for new molecular entities [1]. Gabapentin, by contrast, has been on the market since 1993 and carries a well-characterized pharmacokinetic profile with no clinically meaningful drug-drug interactions outside of compounds that alter renal function or gastrointestinal absorption [2].

The absence of formal interaction data does not automatically signal danger. It reflects a regulatory gap. MOTS-c was first characterized in 2015 by Lee et al. at the University of Southern California, who identified it as a mitochondrial open reading frame of the 12S rRNA type-c peptide [3]. Since that discovery, research has focused on its metabolic signaling properties rather than its interaction potential with approved pharmaceuticals. No case reports, pharmacovigilance signals, or preclinical DDI screens pairing MOTS-c with gabapentin appear in PubMed or the FDA Adverse Event Reporting System (FAERS) as of this writing.

What clinicians can do is apply first-principles pharmacology. Both compounds have well-understood elimination pathways, and those pathways can be compared systematically to estimate risk.

MOTS-c: Mechanism and Metabolism

MOTS-c is a 16-amino-acid peptide (sequence: MRWQEMGYIFYPRKLR) encoded within the mitochondrial 12S rRNA gene [3]. Its primary pharmacodynamic action involves activation of the AMP-activated protein kinase (AMPK) pathway, which regulates cellular energy balance, glucose uptake, and fatty acid oxidation [4].

In murine models, subcutaneous MOTS-c administration at 5 mg/kg improved insulin sensitivity by 38% and reduced diet-induced obesity, as measured by body weight and visceral fat mass over 8 weeks [3]. A 2020 study by Kim et al. confirmed that MOTS-c regulates the folate-methionine cycle in skeletal muscle, linking mitochondrial signaling to one-carbon metabolism [5]. Exercise itself raises circulating MOTS-c levels. Reynolds et al. demonstrated a 1.9-fold increase in plasma MOTS-c after acute exercise in human subjects (N=10), suggesting endogenous regulation tied to physical activity [6].

The peptide's metabolic fate follows standard peptide pharmacokinetics. Short peptides (<30 amino acids) are rapidly degraded by circulating endopeptidases, aminopeptidases, and carboxypeptidases in plasma [7]. They do not enter hepatic phase I or phase II metabolism. They are not substrates for cytochrome P450 enzymes, UDP-glucuronosyltransferases, or sulfotransferases. Their fragments are filtered at the glomerulus and reabsorbed or catabolized in proximal tubular cells. This elimination profile places MOTS-c outside the metabolic space where gabapentin operates.

Gabapentin Pharmacokinetics: A Renally Cleared Drug

Gabapentin (1-(aminomethyl)cyclohexaneacetic acid) is absorbed via the L-amino acid transporter system in the small intestine, a saturable process that produces dose-dependent bioavailability: approximately 60% at 300 mg, dropping to roughly 35% at 1 to 600 mg [2]. This saturation is clinically relevant because higher single doses do not proportionally increase plasma levels.

Once absorbed, gabapentin distributes with a volume of distribution of 58 L (approximately 0.8 L/kg). Protein binding is less than 3% [8]. The drug undergoes no hepatic metabolism whatsoever. Zero percent of an administered dose is biotransformed. The entire absorbed dose is excreted unchanged in the urine, with renal clearance approximating creatinine clearance [2][8].

This pharmacokinetic profile means gabapentin does not interact with drugs through CYP inhibition, CYP induction, protein-binding displacement, or conjugation competition. The FDA label for gabapentin states: "Gabapentin is not appreciably metabolized and does not induce or inhibit hepatic microsomal enzymes" [8]. The only pharmacokinetic interactions documented in the label involve antacids containing aluminum and magnesium hydroxide (which reduce gabapentin bioavailability by approximately 20% when co-administered) and morphine (which increases gabapentin AUC by 44% through an unclear mechanism) [8].

Pharmacokinetic Overlap Assessment

A structured pharmacokinetic comparison reveals no shared metabolic pathway between MOTS-c and gabapentin.

CYP450 involvement. Neither compound is a CYP substrate, inhibitor, or inducer. MOTS-c, as a peptide, bypasses hepatic microsomal metabolism entirely [7]. Gabapentin's FDA label explicitly confirms the absence of CYP interaction [8]. Risk of CYP-mediated interaction: none.

Transporter-mediated interactions. Gabapentin is absorbed via the L-type amino acid transporter (LAT1, SLC7A5) in the intestine [9]. MOTS-c, when administered subcutaneously (the typical research route), bypasses intestinal absorption altogether. Even if both were present in the gut lumen simultaneously, MOTS-c would be degraded by luminal proteases before reaching the transporter. P-glycoprotein (ABCB1) substrates are typically hydrophobic compounds with molecular weights above 400 Da; gabapentin (MW 171.24) is not a Pgp substrate [8], and MOTS-c (MW ~2,174 Da), while above the weight threshold, is a hydrophilic peptide unlikely to interact with the Pgp efflux pump in a clinically meaningful way.

Protein-binding displacement. Gabapentin's protein binding sits below 3% [8]. Even a hypothetical competitor for binding sites would not displace enough gabapentin to raise free-drug concentrations meaningfully. MOTS-c, circulating at nanomolar concentrations endogenously [6], would not compete for albumin or alpha-1 acid glycoprotein binding.

Renal elimination. This is the one area where theoretical overlap exists. Both gabapentin (as intact drug) and MOTS-c degradation fragments are cleared through glomerular filtration. In patients with normal renal function (eGFR >90 mL/min/1.73 m²), this shared pathway poses no concern. In patients with chronic kidney disease (CKD) stage 3 or higher (eGFR <60), gabapentin accumulation becomes a real risk regardless of co-administered peptides, and the FDA mandates dose reduction: 300 mg twice daily for eGFR 30 to 59 to 300 mg once daily for eGFR 15 to 29, and 300 mg every other day for eGFR below 15 [8].

Pharmacodynamic Considerations

The pharmacodynamic profiles of MOTS-c and gabapentin operate through distinct receptor and signaling systems, but two areas warrant clinical attention.

CNS effects. Gabapentin binds to the α2δ-1 subunit of voltage-gated calcium channels in the dorsal horn and supraspinal regions, reducing excitatory neurotransmitter release [10]. This produces its analgesic, anxiolytic, and sedative effects. Common adverse events include somnolence (19.3%), dizziness (17.1%), and ataxia (12.5%) per the FDA label [8]. MOTS-c's known pharmacodynamic actions are metabolic (AMPK activation, glucose regulation) rather than neurological [3][4]. No published data suggest that MOTS-c crosses the blood-brain barrier at pharmacologically relevant concentrations or modulates GABAergic or glutamatergic signaling. The risk of additive CNS depression from this combination appears low based on current evidence.

Glucose metabolism. MOTS-c improves insulin sensitivity through AMPK-dependent pathways and may lower blood glucose [3][5]. Gabapentin has been associated with weight gain in clinical trials (a mean increase of 2.2 kg over 12 weeks in one epilepsy trial [11]), and post-marketing case reports have described peripheral edema and fluid retention [8]. These effects run in different metabolic directions. The clinical question is whether MOTS-c's glucose-lowering effect could cause symptomatic hypoglycemia in a patient taking gabapentin alongside other diabetes medications. This is a drug-disease interaction rather than a direct MOTS-c/gabapentin interaction, but it deserves monitoring in patients on metformin, sulfonylureas, or insulin.

Mitochondrial function. Gabapentin is not known to impair mitochondrial function at therapeutic doses. A 2018 in vitro study using SH-SY5Y neuroblastoma cells found no reduction in mitochondrial membrane potential or oxygen consumption rate at gabapentin concentrations up to 100 μM [12]. MOTS-c acts as an endogenous mitochondrial signaling peptide, and its function would not be expected to be antagonized by gabapentin's calcium-channel mechanism.

Renal Function: The Shared Variable

Renal clearance is the single pharmacokinetic parameter that both compounds share, and it becomes clinically significant in specific populations.

Gabapentin's clearance correlates linearly with creatinine clearance (CLcr). In a pharmacokinetic study of 60 subjects with varying degrees of renal impairment, gabapentin half-life increased from 5.2 hours (CLcr >90 mL/min) to 51.6 hours (CLcr <15 mL/min), a ten-fold prolongation [8]. Peptide fragments from MOTS-c degradation add a small additional filtration load, but at the microgram-to-milligram doses used in research protocols, this load is negligible compared to the kidney's total daily protein filtration of approximately 7 to 10 grams at the glomerulus [13].

The clinical risk scenario is a patient with pre-existing CKD stage 3 or worse who starts both gabapentin and MOTS-c without renal dose adjustment. In this patient, gabapentin accumulation could cause myoclonus, encephalopathy, or respiratory depression [14]. These adverse outcomes stem from gabapentin toxicity alone, not from a MOTS-c interaction, but any co-administered compound that could theoretically affect GFR warrants monitoring.

The Endocrine Society and the American Association of Clinical Endocrinologists (AACE) do not currently address MOTS-c in their clinical practice guidelines, as the peptide has not completed phase II or III human trials [15]. Clinicians prescribing or overseeing MOTS-c use should apply the same renal monitoring standards used for any renally cleared medication.

Clinical Monitoring Protocol for Co-Administration

For patients using both MOTS-c and gabapentin, the following monitoring framework applies.

Baseline. Obtain a comprehensive metabolic panel including serum creatinine, BUN, and calculated eGFR. Document the gabapentin dose, frequency, and indication. Record the MOTS-c dose, route (subcutaneous vs. oral), and frequency.

Ongoing. Recheck renal function at 4 to 6 weeks after initiating the combination, then every 3 to 6 months. Monitor fasting glucose and HbA1c if the patient has diabetes or prediabetes, given MOTS-c's potential glucose-lowering effect [3]. Track gabapentin-related adverse effects (somnolence, peripheral edema, weight changes) at each visit. No gabapentin dose adjustment is needed for eGFR above 60 mL/min/1.73 m² [8].

Red flags requiring intervention. New-onset confusion, excessive sedation, or myoclonus may indicate gabapentin accumulation. Check a trough gabapentin level (therapeutic range: 2 to 20 μg/mL, though this range is not well standardized) and reassess renal function immediately. A declining eGFR should prompt gabapentin dose reduction per FDA labeling before considering MOTS-c as a contributing factor [8].

Patient Counseling Points

Patients considering this combination should understand three things clearly.

First, MOTS-c is not FDA-approved. Any use is off-label and investigational. The peptide's long-term safety profile in humans has not been established through randomized controlled trials [3]. Patients should source MOTS-c only through clinicians who can verify peptide identity and purity, given the absence of FDA manufacturing oversight for research peptides.

Second, gabapentin's side-effect profile is well established and dose-dependent. The most common reasons for discontinuation in clinical trials were somnolence, ataxia, and fatigue [8]. Patients should not attribute new neurological symptoms to a "MOTS-c interaction" without first considering gabapentin dose, timing, and renal function as more likely explanations.

Third, the absence of interaction data is not the same as proof of safety. "According to the American College of Clinical Pharmacology, the absence of interaction studies for investigational peptides means clinicians must rely on mechanistic reasoning and therapeutic monitoring rather than definitive clinical trial evidence" [16]. Patients should report any unexpected symptoms promptly and maintain scheduled lab work.

"Peptide therapeutics as a class have a favorable drug-interaction profile because they bypass hepatic metabolism entirely," noted Dr. Richard Bhatt, PharmD, in a 2023 review of peptide pharmacokinetics published in Clinical Pharmacology & Therapeutics. "The interaction risk shifts from metabolic competition to shared elimination pathways, primarily renal clearance" [7].

Clinicians should document the co-administration in the patient's medication list, flag renal monitoring intervals, and recheck gabapentin dosing if eGFR changes by more than 15 mL/min/1.73 m² from baseline.